GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

Original reporting
Published Nov 18, 2026, 3:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The FDA accelerated approval provides a new US revenue stream and de-risks part of the acquisition thesis, but the article emphasizes that first-line expansion is the main value driver and depends on ongoing Phase III results.

02

Market read

Traders can reassess GSK’s oncology pipeline value after a fresh FDA approval, while monitoring the next catalyst tied to first-line label expansion.

03

What to watch

The article does not quantify pricing, uptake, or safety profile; investors may need additional data on tolerability versus Alecensa and real-world prescribing behavior.

Relevance 8/10Novelty 3/10Timing: FDA approval reported today, with commercial implications for GSK’s lung-cancer pipeline.

Background

GSK acquired Nuvalent for $10.6bn mid-July, and Nelkarmi is the second lung-cancer drug to reach market from that portfolio.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA approved GSK’s Nelkarmi (neladalkib) for ALK-positive NSCLC, the second product from its $10.6bn Nuvalent takeover.

Expected impact

Likely positive repricing as investors underwrite incremental revenue from a new FDA-approved ALK inhibitor, tempered by uncertainty around first-line adoption.

Evidence & confidence

The article is a direct FDA approval with trial-based efficacy metrics, while also flagging that first-line expansion depends on ongoing ALKAZAR Phase III results.

Market effects

Reinforces competitive intensity in ALK-positive NSCLC and highlights the importance of CNS penetration and resistance-mutation coverage.

US FDA approval can shift near-term sentiment for global pharma with oncology assets, especially those with US commercialization gaps.

US label expansion expectations can influence global ALK inhibitor competitive positioning and partner/competitor valuation narratives.

Counterpoint

Near-term upside may be limited if Nelkarmi’s uptake stays concentrated in previously treated patients, with first-line adoption delayed by ALKAZAR Phase III outcomes.

Key entities

  • GSK

    British pharma issuer of Nelkarmi, approved by the FDA for ALK-positive NSCLC.

  • Nuvalent

    Pipeline source acquired by GSK for $10.6bn; Nelkarmi and Jideytro are products from its portfolio.

  • FDA

    Approved Nelkarmi accelerated approval for previously treated ALK-positive NSCLC.

  • Roche

    Alecensa is cited as a main competitor to Nelkarmi.

Related articles

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.

$GSKMed

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).